Chat with Filing

Ask questions about this document
Please log in or register to use the chat feature. Please register first.
MANG - SCHOTT Pharma Supervisory Board extends contract of CEO Andreas Reisse and appoints Reinhard Mayer as new CFO

Company: Schott Pharma Date: 2025-06-11 Language: English Register to download
Loading document preview...
Document Preview Not Available

The file type (.html) cannot be displayed directly here.
Open Original File
Error loading document preview. Please try the 'Open Original File' link.
You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:
Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon
 News Details 

Corporate | 11 June 2025 08:50

#   

SCHOTT Pharma Supervisory Board extends contract of CEO Andreas Reisse and appoints Reinhard Mayer as new CFO

SCHOTT Pharma AG & Co. KGaA / Key word(s): Personnel/Contract  

SCHOTT Pharma Supervisory Board extends contract of CEO Andreas Reisse and appoints Reinhard Mayer as new CFO  

  

11.06.2025 / 08:50 CET/CEST  

The issuer is solely responsible for the content of this announcement.  

  

- - -

**SCHOTT Pharma Supervisory Board extends contract of CEO Andreas Reisse and appoints Reinhard Mayer as new CFO**

-   Andreas Reisse’s contract as CEO of SCHOTT Pharma extended
-   CFO Dr. Almuth Steinkühler to leave the company at her own request to pursue new professional opportunities
-   Reinhard Mayer appointed as new CFO of SCHOTT Pharma

**The Supervisory Board of SCHOTT Pharma Management AG has decided to extend the appointment of Andreas Reisse as CEO of SCHOTT Pharma until April 2026. His contract will thus continue until he reaches the age limit of 65 years for members of the Executive Board, as stipulated in the Articles of Association. Andreas Reisse has been with the SCHOTT Group since 1987 and has led the “Pharmaceutical Systems” division since 2010, which has been listed on the Frankfurt Stock Exchange as SCHOTT Pharma AG & Co. KGaA since 2023. “Andreas Reisse has played a key role in developing SCHOTT Pharma into one of the world’s leading pioneers in pharmaceutical containment solutions and delivery systems. We are delighted that he will continue to lead SCHOTT Pharma for another year, driving innovation and generating sustainable growth by expanding the company’s global presence,” said Peter Goldschmidt, Chairman of the Supervisory Board of SCHOTT Pharma AG & Co. KGaA.**

“I would like to thank the Supervisory Board for their continued trust. Together, we have delivered industry-leading innovations, achieved remarkable growth, and improved the health of many people in a sustainable way. We have big plans for the future. Our sector remains dynamic and full of opportunity, and I look forward to working with the entire SCHOTT Pharma team to achieve our ambitious goals,” said Andreas Reisse, CEO of SCHOTT Pharma.

**Reinhard Mayer to succeed Dr. Almuth Steinkühler**

CFO Dr. Almuth Steinkühler informed the Supervisory Board that she does not seek another term in office. She will leave SCHOTT Pharma at her own request after her current contract expires on July 31, 2025, to pursue new professional challenges. “On behalf of the entire Supervisory Board, I would like to thank Almuth Steinkühler for her outstanding contributions to the success of SCHOTT Pharma over the past years. With her expertise and international experience, she has established key processes and an infrastructure that have made SCHOTT Pharma ready for the capital market and successfully led the company to its IPO. As a key figure representing SCHOTT Pharma on the capital market, she has strengthened investor confidence with her professionalism and foresight. With her outstanding leadership skills, she has also played a decisive role in shaping the strategic and operational development of SCHOTT Pharma, setting the course for sustainable growth and elevating the company’s communications to a new level. We wish her all the best for her personal and professional future,” said Peter Goldschmidt, Chairman of the Supervisory Board of SCHOTT Pharma AG Co. KGaA.

Andreas Reisse added: “I would like to personally thank Almuth, who has been a fantastic partner on SCHOTT Pharma’s growth journey over the past years. She played a key role in transforming SCHOTT Pharma into a successful listed company.”

Reinhard Mayer will succeed Dr. Almuth Steinkühler on August 1, 2025. A graduate in industrial engineering, he looks back on many years of experience in corporate finance, controlling, and IT, including over 20 years in CFO positions. Mayer brings a wealth of perspectives from leading diverse global teams in multinational, publicly traded companies. In his most recent position as CFO of Denmark-listed Nilfisk Holding A/S, Mayer played a key role in shaping the company’s strategy for organic growth, overseeing financial consolidation and optimizing and digitizing business processes. Before that, he served as CFO on the Executive Board of Hansgrohe SE and spent 15 years in various global management positions, most recently as CFO at the Getinge Group, a publicly listed medical technology group based in Sweden.

“We are delighted to welcome Reinhard Mayer as Chief Financial Officer of SCHOTT Pharma. Reinhard Mayer is not only a proven expert in finance with supply chain experience in the life sciences sector, but also an outstanding leader. In various management positions in his career, Reinhard Mayer has successfully shaped the financial and strategic orientation of several global companies, digitized processes, increased the efficiency of global structures in corporations with billions in sales, and successfully completed numerous M&A projects. We are confident that Reinhard Mayer will play a key role in continuing SCHOTT Pharma’s growth trajectory and success story as a publicly listed company,” Peter Goldschmidt continued.

“I warmly welcome Reinhard to our team. His impressive experience and strong personality make him a valuable addition to SCHOTT Pharma’s team. I look forward to working together in the future,” said Andreas Reisse.

Commenting on his appointment, Reinhard Mayer, the designated CFO, said: “I would like to thank the Supervisory Board and everyone involved for the trust they have placed in me. SCHOTT Pharma has an impressive track record. I am joining a company with a strong equity story, dynamic and profitable growth, excellent technological leadership, and a highly motivated and committed team. I am excited to contribute to this success story in one of the fastest-growing pharmaceutical markets as part of the team.”

*For further news about SCHOTT Pharma, please visit our* [Media Center](https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=30f4057dfd921d5b76e40c551d202dfc&application_id=2153192&site_id=airport_aws~~~7cc68db1-74de-43c8-af69-2ae0a97efdc3&application_name=news) *.*

**About SCHOTT Pharma**

Human health matters. That is why SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world. Every minute, more than 25,000 people receive an injection packed in a SCHOTT Pharma product. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,700 people from over 60 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 17 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the SDAX. It is majority owned by SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 957 million in the fiscal year 2024. Further information at www.schott-pharma.com

**Press contact**

Lea Kaiser  

Media Relations  

Tel.: +49 (0) 6131 66-2422  

E-Mail: [lea.kaiser@schott.com](mailto:lea.kaiser@schott.com)

Tobias Erfurth  

Head of Investor Relations  

E-Mail: [ir.pharma@schott.com](mailto:ir.pharma@schott.com)

Jasko Terzic, CFA  

Senior Manager Investor Relations  

E-Mail: [ir.pharma@schott.com](mailto:ir.pharma@schott.com)

  

- - -

11.06.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.  

The issuer is solely responsible for the content of this announcement.  

  

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.  

Archive at www.eqs-news.com  

- - -

|     |     |
| --- | --- |
| Language: | English |
| Company: | SCHOTT Pharma AG & Co. KGaA |
|     | Hattenbergstraße 10 |
|     | 55122 Mainz |
|     | Germany |
| ISIN: | DE000A3ENQ51 |
| WKN: | A3ENQ5 |
| Indices: | SDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2153192 |

  

|     |     |
| --- | --- |
|     |     |
| End of News | EQS News Service |

- - -

2153192  11.06.2025 CET/CEST

![](https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2153192&application_name=news&site_id=airport_aws~~~7cc68db1-74de-43c8-af69-2ae0a97efdc3)